# Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

> **NCT01687387** · PHASE2 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 152 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** IPH2102 at 0.1 mg/kg
- **DRUG:** IPH2102 at 1 mg/kg
- **DRUG:** Placebo (normal saline solution)

## Key facts

- **NCT ID:** NCT01687387
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-11-17
- **Final completion:** 2016-11-17
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687387, "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01687387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*